Navidea Biopharmaceuticals (NYSE:NAVB) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Shares of NAVB stock opened at $0.04 on Monday. The stock’s fifty day moving average is $0.04 and its 200-day moving average is $0.05. The stock has a market capitalization of $3.81 million, a PE ratio of -0.64 and a beta of 1.13. Navidea Biopharmaceuticals has a 52 week low of $0.02 and a 52 week high of $0.27.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.